Weekly Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
During 2018 Q2 the big money sentiment decreased to 1.89. That’s change of 0.55, from 2018Q1’s 2.44. 16 investors sold all, 12 reduced holdings as Dicerna Pharmaceuticals, Inc. ratio turned negative. 18 grew positions while 35 funds amassed positions. Funds hold 36.31 million shares thus 18.35% more from 2018Q1’s 30.68 million shares.
Artal Group Incorporated, a Luxembourg-based fund reported 425,000 shs. Dimensional Fund Lp invested 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Renaissance Technologies Llc holds 0% or 289,400 shs in its capital. Piedmont Investment Advisors Limited Liability Com reported 771 shs. Emory University owns 179,568 shs. The Massachusetts-based Panagora Asset Mgmt Incorporated has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). The Illinois-based Northern Trust has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). 551,814 are owned by Goldman Sachs Grp Inc. 2.61M were accumulated by Blackrock Inc. Citadel Advisors Ltd Liability has invested 0.01% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Deutsche Bancshares Ag accumulated 370,695 shs. 9,210 are owned by Bancorp Of America De. Tower Rech Capital Ltd Liability (Trc) has 797 shs. Voya Invest Mngmt Ltd Liability Com accumulated 16,987 shs. Emerald Advisers Pa invested 0.28% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Dicerna Pharmaceuticals, Inc. registered $12.83 million net activity with 0 buys and 4 selling transactions since August 15, 2018. Halak Brian K had sold 564,300 shs worth $7.71M. On Wednesday, August 15 LANGER DENNIS sold $613,456 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

A total of 5 analysts rate Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 5 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:DRNA) has 7 ratings reports on Dec 8, 2018 according to StockzIntelligence. On Monday, September 17 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Neutral” rating by FBR Capital. On Tuesday, November 6 the company was upgraded by FBR Capital. On Wednesday, August 15 the firm has “Buy” rating given by H.C. Wainwright. On Thursday, August 9 Stifel Nicolaus maintained the shares of DRNA in report with “Buy” rating. In Tuesday, October 30 report Citigroup maintained the stock with “Buy” rating. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

28/11/2018 Broker: Leerink Swann Rating: Outperform New Target: $24 Initiates Coverage On
06/11/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $13.5 New Target: $21 Upgrade
30/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $30 Maintain
17/09/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Neutral Old Target: $10 New Target: $13.5 Maintain
13/09/2018 Broker: Citigroup Rating: Buy New Target: $27 Initiates Coverage On
15/08/2018 Broker: H.C. Wainwright Old Rating: Neutral New Rating: Buy Upgrade
09/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain

DRNA is hitting $12.74 during the last trading session, after decreased 8.74%.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 325.07% change in last December 8, 2017. DRNA has also 393,230 shares volume. The stock outperformed the S&P500 by 309.45%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is worth $799.20 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

For more Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news published recently go to: Seekingalpha.com, Businesswire.com, Stockhouse.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Dicerna announces proof of concept for DCR-PHXC in the treatment of primary hyperoxaluria – Seeking Alpha” published on September 05, 2018, “Dicerna to Participate in Upcoming Investor Conferences – Business Wire” on November 06, 2018, “Leerink Starts Coverage Of Genetic Medicine Stocks: ‘We See Commercial Execution As Increasingly Driving Returns’ – Stockhouse” with a publish date: November 28, 2018, “Dicerna Pharmaceuticals: Institutional Buying Heats Up – Seeking Alpha” and the last “Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” with publication date: November 30, 2018.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.